{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:12:57Z","timestamp":1792872777715,"version":"4.5.0"},"reference-count":89,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Focal segmental glomerulosclerosis (FSGS) is a histopathological pattern of segmental glomerulosclerosis that arises from diverse primary and secondary causes. Primary (idiopathic) FSGS is rare and is often linked to intrinsic podocyte injury, while secondary forms are more prevalent and may reflect adaptative, toxic, genetic, or viral etiologies. This pattern of injury can lead to progressive renal dysfunction and, in some cases, end-stage kidney disease. The pathophysiology is multifactorial and includes direct podocyte injury (e.g., genetic defects, mechanical or toxic injury), immune-mediated processes (e.g., circulating permeability factors, inflammatory mediators), and metabolic disturbances. In particular, disturbance of lipid metabolism, including intracellular cholesterol accumulation in podocytes, have been implicated as a contributory mechanism in podocyte dysfunction and progression of disease in proteinuric\/nephrotic presentations and in specific disease subtypes. Diagnosis relies on clinical assessment, laboratory testing, and histological examination, with kidney biopsy remaining the gold standard. Conventional treatments include corticosteroids, and other immunosuppressants when indicated, and measures to reduce proteinuria and control blood pressure, but the therapeutic response is variable and many patients show progression, highlighting the need for more effective and novel therapeutic approaches. Cyclodextrins (CDs), widely used as drug carriers to enhance solubility, can also mobilize and promote efflux of cholesterol from cells. Preclinical studies show that CDs reduce renal lipid accumulation and ameliorate podocyte injury in experimental models, supporting the idea that CDs could have a dual role as drug carriers and as direct modulators of lipid-related podocyte injury in lipid-associated forms of FSGS. Given the limited direct clinical data in FSGS, in this article we discuss the biological rationale, preclinical evidence, and remaining knowledge gaps for exploring CDs as an innovative therapeutic strategy.<\/jats:p>","DOI":"10.3390\/ijms26188760","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:27:12Z","timestamp":1757500032000},"page":"8760","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Focal Segmental Glomerulosclerosis: Comprehensive Review and Exploration of the Dual Potential of Cyclodextrins in Therapeutic Optimization"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0786-6280","authenticated-orcid":false,"given":"Filipa","family":"Mascarenhas-Melo","sequence":"first","affiliation":[{"name":"Higher School of Health, Polytechnic Institute of Guarda, Rua da Cadeia, 6300-307 Guarda, Portugal"},{"name":"BRIDGES\u2014Biotechnology Research, Innovation and Design for Health Products, Polytechnic University of Guarda, Avenida Dr. Francisco S\u00e1 Carneiro, No. 50, 6300-559 Guarda, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Martins","sequence":"additional","affiliation":[{"name":"Higher School of Health, Polytechnic Institute of Guarda, Rua da Cadeia, 6300-307 Guarda, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Higher School of Health, Polytechnic Institute of Guarda, Rua da Cadeia, 6300-307 Guarda, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2580-7524","authenticated-orcid":false,"given":"Alka","family":"Lohani","sequence":"additional","affiliation":[{"name":"Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida 201313, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9645-4020","authenticated-orcid":false,"given":"Karolline","family":"Krambeck","sequence":"additional","affiliation":[{"name":"Higher School of Health, Polytechnic Institute of Guarda, Rua da Cadeia, 6300-307 Guarda, Portugal"},{"name":"BRIDGES\u2014Biotechnology Research, Innovation and Design for Health Products, Polytechnic University of Guarda, Avenida Dr. Francisco S\u00e1 Carneiro, No. 50, 6300-559 Guarda, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2228701","DOI":"10.1001\/jamanetworkopen.2022.28701","article-title":"Comparing Kidney Health Outcomes in Children, Adolescents, and Adults with Focal Segmental Glomerulosclerosis","volume":"5","author":"Gipson","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e14545","DOI":"10.14814\/phy2.14545","article-title":"Nanoparticles exhibit greater accumulation in kidney glomeruli during experimental glomerular kidney disease","volume":"8","author":"Liu","year":"2020","journal-title":"Physiol. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Pekkucuksen, N.T., Liu, L.P., Aly, R., Shoemaker, L.R., and Alli, A.A. (2022). Extracellular vesicles from focal segmental glomerulo-sclerosis pediatric patients induce STAT3 activation and mesangial cell proliferation. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0274598"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"27546","DOI":"10.1097\/MD.0000000000027546","article-title":"Pembrolizumab-induced focal segmental glomerulosclerosis: A case report","volume":"100","author":"Kim","year":"2021","journal-title":"Medicine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1053\/j.akdh.2024.03.009","article-title":"Focal Segmental Glomerulosclerosis","volume":"31","author":"Suresh","year":"2024","journal-title":"Adv. Kidney Dis. Health"},{"key":"ref_6","unstructured":"Newswire, G. (2025, April 03). Focal Segmental Glomerulosclerosis (FSGS) Epidemiology Forecast, 2024-2034\u2014FSGS Prevalence Higher Among Males, Peaks in 18\u201364 Age Group Across the 7MM. Available online: https:\/\/www.globenewswire.com\/news-release\/2024\/04\/26\/2870588\/28124\/en\/Focal-Segmental-Glomerulosclerosis-FSGS-Epidemiology-Forecast-2024-2034-FSGS-Prevalence-Higher-Among-Males-Peaks-in-18-64-Age-Group-Across-the-7MM.html."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00467-006-0370-5","article-title":"Focal segmental glomerulosclerosis-epidemiology aspects in children and adults","volume":"22","author":"Hogg","year":"2007","journal-title":"Pediatr. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2215\/CJN.05960616","article-title":"Focal Segmental Glomerulosclerosis","volume":"12","author":"Rosenberg","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_9","first-page":"949","article-title":"Corrigendum to Novel Treatment Paradigms: Focal Segmental Glomerulosclerosis Kidney International Reports, Volume 8, Issue 1, January 2023, Pages 30\u201335","volume":"9","author":"Meliambro","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4132\/jptm.2016.09.21","article-title":"Pathogenesis of Focal Segmental Glomerulosclerosis","volume":"50","author":"Fogo","year":"2016","journal-title":"J. Pathol. Transl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1159\/000508099","article-title":"Focal Segmental Glomerulosclerosis: State-of-the-Art and Clinical Perspective","volume":"144","author":"Shabaka","year":"2020","journal-title":"Nephron"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.akdh.2024.10.004","article-title":"Podocytopathies","volume":"32","author":"Wooden","year":"2025","journal-title":"Adv. Kidney Dis. Health"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.nefro.2023.04.005","article-title":"Expresi\u00f3n de C4d en glomeruloesclerosis focal y segmentaria","volume":"44","author":"Cruz","year":"2024","journal-title":"Nefrolog\u00eda"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/ckj\/sfad161","article-title":"Focal segmental glomerulosclerosis associated with the use of the IL-23 inhibitor guselkumab","volume":"16","author":"Stryckers","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nrneph.2011.151","article-title":"The podocyte cytoskeleton\u2014Key to a functioning glomerulus in health and disease","volume":"8","author":"Welsh","year":"2012","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1053\/j.ackd.2014.05.009","article-title":"The Pathogenesis of Focal Segmental Glomerulosclerosis","volume":"21","author":"Jefferson","year":"2014","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1681\/ASN.2017090958","article-title":"Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach","volume":"29","author":"Sethi","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/nrneph.2014.216","article-title":"Causes and pathogenesis of focal segmental glomerulosclerosis","volume":"11","author":"Fogo","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Merscher, S., Pedigo, C.E., and Mendez, A.J. (2014). Metabolism, Energetics, and Lipid Biology in the Podocyte\u2014Cellular Cholesterol-Mediated Glomerular Injury. Front. Endocrinol., 5.","DOI":"10.3389\/fendo.2014.00169"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1053\/j.ajkd.2016.03.416","article-title":"Distribution of Biopsy-Proven Presumed Primary Glomerulonephropathies in 2000\u20132011 Among a Racially and Ethnically Diverse US Population","volume":"68","author":"Sim","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/snep.2003.50025","article-title":"Trends in the epidemiology of focal segmental glomerulosclerosis","volume":"23","author":"Kitiyakara","year":"2003","journal-title":"Semin. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s00508-023-02260-x","article-title":"Diagnosis and treatment of focal-segmental glomerulosclerosis\u20142023","volume":"135","author":"Gauckler","year":"2023","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5493\/wjem.v13.i3.7","article-title":"Physiopathological mechanisms related to inflammation in obesity and type 2 diabetes mellitus","volume":"13","author":"Lempesis","year":"2023","journal-title":"World J. Exp. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MNH.0b013e3283414ca1","article-title":"Is there an obesity-metabolic syndrome related glomerulopathy?","volume":"20","author":"Ritz","year":"2011","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Podest\u00e0, M.A., and Ponticelli, C. (2020). Autoimmunity in Focal Segmental Glomerulosclerosis: A Long-Standing Yet Elusive Association. Front. Med., 7.","DOI":"10.3389\/fmed.2020.604961"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/14728214.2020.1803276","article-title":"Emerging drugs for treatment of focal segmental glomerulosclerosis","volume":"25","author":"Trachtman","year":"2020","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.drudis.2015.11.017","article-title":"Cyclodextrins in pharmaceutical formulations I: Structure and physicochemical properties, for-mation of complexes, and types of complex","volume":"21","author":"Jambhekar","year":"2016","journal-title":"Drug Discov. Today"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.2174\/1389450121666200615150039","article-title":"Characteristic of Cyclodextrins: Their Role and Use in the Pharmaceutical Technology","volume":"21","author":"Lachowicz","year":"2020","journal-title":"Curr. Drug Targets"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101408","DOI":"10.1016\/j.progpolymsci.2021.101408","article-title":"Cyclodextrin polymers: Structure, synthesis, and use as drug carriers","volume":"118","author":"Liu","year":"2021","journal-title":"Prog. Polym. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.kint.2015.12.058","article-title":"Drug discovery in focal and segmental glomerulosclerosis","volume":"89","author":"Pullen","year":"2016","journal-title":"Kidney Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1046\/j.1523-1755.2002.00674.x","article-title":"Treatment of primary focal segmental glomerulosclerosis","volume":"62","author":"Korbet","year":"2002","journal-title":"Kidney Int."},{"key":"ref_32","first-page":"265","article-title":"Glomeruloesclerose focal e segmentar: Avan\u00e7os no diagn\u00f3stico e consenso no tratamento","volume":"14","author":"Garcia","year":"2020","journal-title":"CuidArte Enferm"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000530344","article-title":"Therapeutic Potential Targeting Podocyte Mitochondrial Dysfunction in Focal Segmental Glomerulosclerosis","volume":"9","author":"Li","year":"2023","journal-title":"Kidney Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/BF00866790","article-title":"Focal segmental glomerulosclerosis","volume":"10","author":"Ichikawa","year":"1996","journal-title":"Pediatr. Nephrol."},{"key":"ref_35","unstructured":"Saleh, Z. (2025, April 03). Focal Segmental Glomerulosclerosis. Available online: https:\/\/medizzy.com\/feed\/40232972."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1681\/ASN.2014050489","article-title":"A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome","volume":"26","author":"Sadowski","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1056\/NEJMra1106556","article-title":"Focal segmental glomerulosclerosis","volume":"365","author":"Kaskel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1681\/ASN.V971333","article-title":"Primary focal segmental glomerulosclerosis","volume":"9","author":"Korbet","year":"1998","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1126\/science.1193032","article-title":"Association of trypanolytic ApoL1 variants with kidney disease in African Americans","volume":"329","author":"Genovese","year":"2010","journal-title":"Science"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2215\/CJN.15161219","article-title":"APOL1 Nephropathy: From Genetics to Clinical Applications","volume":"16","author":"Friedman","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Otalora, L., Chavez, E., Watford, D., Tueros, L., Correa, M., Nair, V., Ruiz, P., Wahl, P., Eddy, S., and Martini, S. (2019). Identification of glomerular and podocyte-specific genes and pathways activated by sera of patients with focal segmental glomerulosclerosis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0222948"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev-pathol-051220-092001","article-title":"Pathogenesis of Focal Segmental Glomerulosclerosis and Related Disorders","volume":"20","author":"Altintas","year":"2025","journal-title":"Annu. Rev. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Lan, X., Rao, T.K.S., Chander, P.N., Skorecki, K., and Singhal, P.C. (2015). Apolipoprotein L1 (APOL1) Variants (Vs) a possible link between Heroin-associated Nephropathy (HAN) and HIV-associated Nephropathy (HIVAN. Front. Microbiol., 6.","DOI":"10.3389\/fmicb.2015.00571"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Zhan, H.Q., Zhang, X., Chen, X.L., Cheng, L., and Wang, X. (2024). Application of nanotechnology in the treatment of glomerulonephritis: Current status and future perspectives. J. Nanobiotechnol., 22.","DOI":"10.1186\/s12951-023-02257-8"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.ekir.2023.01.031","article-title":"Identification of Glomerular and Plasma Apolipoprotein M as Novel Biomarkers in Glomerular Disease","volume":"8","author":"Drexler","year":"2023","journal-title":"Kidney Int. Reports"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s00424-017-2023-x","article-title":"Focal segmental glomerulosclerosis; why does it occur segmentally?","volume":"469","author":"Nagata","year":"2017","journal-title":"Pflugers Arch. Eur. J. Physiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1053\/j.ajkd.2020.04.014","article-title":"Proteinuria Reduction and Kidney Survival in Focal Segmental Glomerulosclerosis","volume":"77","author":"Troost","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"ref_50","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021). KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int., 100, S1\u2013S276."},{"key":"ref_51","unstructured":"National Institute for Health and Care Excellence (NICE) (2021). Chronic Kidney Disease: Assessment and Management, NICE."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ajt.2023.12.010","article-title":"Efficacy of combined rituximab and dara-tumumab treatment in posttransplant recurrent focal segmental glomerulosclerosis","volume":"24","author":"Angeletti","year":"2024","journal-title":"Am. J. Transplant."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"100457","DOI":"10.1016\/j.xkme.2022.100457","article-title":"Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulo-sclerosis Treatment: A Systematic Review and Meta-Analysis","volume":"4","author":"Campbell","year":"2022","journal-title":"Kidney Med."},{"key":"ref_54","first-page":"418","article-title":"Sparsentan versus irbesartan in focal segmental glomerulosclerosis","volume":"105","author":"Fogo","year":"2014","journal-title":"Kidney Int."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.56083\/RCV4N3-174","article-title":"Glomerulonefrose segmentar e focal\u2014Resposta \u00e0 corticoterapia: Relato de caso","volume":"4","author":"Costa","year":"2024","journal-title":"Rev. Contemp."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Xing, C., Zheng, X., Deng, T., Zeng, L., Liu, X., and Chi, X. (2023). The Role of Cyclodextrin in the Construction of Nanoplatforms: From Structure, Function and Application Perspectives. Pharmaceutics, 15.","DOI":"10.20944\/preprints202304.0334.v1"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"132467","DOI":"10.1016\/j.foodchem.2022.132467","article-title":"Cyclodextrins inclusion complex: Preparation methods, analytical techniques and food industry applications","volume":"384","author":"Rakmai","year":"2022","journal-title":"Food Chem."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Nicolaescu, O.E., Belu, I., Mocanu, A.G., Manda, V.C., R\u0103u, G., P\u00eervu, A.S., Ionescu, C., Ciulu-Costinescu, F., Popescu, M., and Cioc\u00eelteu, M. (2025). V Cyclodextrins: Enhancing Drug Delivery, Solubility and Bioavailability for Modern Therapeutics. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17030288"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e20201783","DOI":"10.1590\/0001-3765202320201783","article-title":"\u03b2-Cyclodextrins alter the energy metabolism-related enzyme activities in rats","volume":"95","author":"Ianiski","year":"2023","journal-title":"An. Acad. Bras. Cienc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"119880","DOI":"10.1016\/j.carbpol.2022.119880","article-title":"Integration of cyclodextrins and associated toxicities: A roadmap for high quality biomedical applications","volume":"295","author":"Trotta","year":"2022","journal-title":"Carbohydr. Polym."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Almeida, B., Domingues, C., Mascarenhas-Melo, F., Silva, I., Jarak, I., Veiga, F., and Figueiras, A. (2023). The Role of Cyclodextrins in COVID-19 Therapy\u2014A Literature Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032974"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Coisne, C., Hallier-Vanuxeem, D., Boucau, M.C., Hachani, J., Tilloy, S., Bricout, H., Monflier, E., Wils, D., Serpelloni, M., and Parissaux, X. (2016). \u03b2-cyclodextrins decrease cholesterol release and ABC-associated transporter expression in smooth muscle cells and aortic endothelial cells. Front. Physiol., 7.","DOI":"10.3389\/fphys.2016.00185"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10311-024-01782-8","article-title":"The revival of cyclodextrins as active pharmaceutical ingredients","volume":"23","author":"Kfoury","year":"2024","journal-title":"Environ. Chem. Lett."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ijbiomac.2016.03.012","article-title":"Physico-chemical properties of corn starch modified with cyclodextrin glycosyltransferase","volume":"87","author":"Dura","year":"2016","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Paiva-Santos, A.C., Ferreira, L., Peixoto, D., Silva, F., Soares, M.J., Zeinali, M., Zafar, H., Mascarenhas-Melo, F., Raza, F., and Mazzola, P.G. (2022). Cyclodextrins as an encapsulation molecular strategy for volatile organic compounds\u2014Pharmaceutical applications. Colloids Surf. B Biointerfaces, 218.","DOI":"10.1016\/j.colsurfb.2022.112758"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3109\/10717544.2014.938839","article-title":"Exploring versatile applications of cyclodextrins: An overview","volume":"23","author":"Sharma","year":"2016","journal-title":"Drug Deliv."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/jps.10126","article-title":"Characterization of the interaction of 2-hydroxypropyl-\u03b2-cyclodextrin with itraconazole at pH 2, 4, and 7","volume":"91","author":"Peeters","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"ref_68","unstructured":"National Library of Medicine, PubChem (2025, June 20). Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/beta-Cyclodextrin-sulfobutyl-ether#section=2D-Structure."},{"key":"ref_69","unstructured":"National Library of Medicine, PubChem (2025, June 20). Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Hydroxypropyl-gamma-cyclodextrin."},{"key":"ref_70","unstructured":"Sielc (2025, June 20). alpha-CYCLODEXTRIN. Available online: https:\/\/sielc.com\/alpha-cyclodextrin."},{"key":"ref_71","unstructured":"Sielc (2025, June 20). beta-CYCLODEXTRIN. Available online: https:\/\/sielc.com\/b-cyclodextrin."},{"key":"ref_72","unstructured":"Sielc (2025, June 20). Gamma-Cyclodextrin. Available online: https:\/\/sielc.com\/gamma-cyclodextrin."},{"key":"ref_73","first-page":"575","article-title":"Cyclodextrin complexes of a globular protein and a lipophilic oligopeptide: The effect of structure and physicochemical properties","volume":"72","author":"Saokham","year":"2017","journal-title":"Pharmazie"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Sciortino, M.T., Dannenberger, D., and Santos Braga, S. (2023). Molecular Mind Games: The Medicinal Action of Cyclodextrins in Neurodegenerative Diseases. Biomolecules, 13.","DOI":"10.3390\/biom13040666"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Cirri, M., Maestrelli, F., Mura, P., Ghelardini, C., and Mannelli, L.D.C. (2018). Combined Approach of Cyclodextrin Complexation and Nanostructured Lipid Carriers for the Development of a Pediatric Liquid Oral Dosage Form of Hydrochlorothiazide. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10040287"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Lopalco, A., Manni, A., Keeley, A., Haider, S., Li, W., Lopedota, A., Altomare, C.D., Denora, N., and Tuleu, C. (2022). In Vivo Inves-tigation of (2-Hydroxypropyl)-\u03b2-cyclodextrin-Based Formulation of Spironolactone in Aqueous Solution for Paediatric Use. Pharma-ceutics, 14.","DOI":"10.3390\/pharmaceutics14040780"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10847-024-01255-z","article-title":"Prediction of the free energy of binding for cyclodextrin-steroid complexes: Phase solubility and molecular dynamics studies","volume":"104","author":"Fereidounpour","year":"2024","journal-title":"J. Incl. Phenom. Macrocycl. Chem."},{"key":"ref_78","first-page":"974","article-title":"Long Term Stability and In-vitro Release Study of Telmisartan Complex included by Hydroxypropyl-beta-cyclodextrin in Directly Compressed Tablet Using Ion-pair Reversed Phase High-performance Liquid Chromatography","volume":"11","author":"Hasson","year":"2021","journal-title":"Int. J. Drug Deliv. Technol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.2147\/IJN.S255636","article-title":"Solid Lipid Nanoparticles of Mycophenolate Mofetil: An Attempt to Control the Release of an Immunosuppressant","volume":"15","author":"Iqbal","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.molliq.2017.12.006","article-title":"Effect of \u03b2-cyclodextrin and different surfactants on solubility, stability, and permeability of hydrochlorothiazide","volume":"250","author":"Altamimi","year":"2018","journal-title":"J. Mol. Liq."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"89","DOI":"10.22159\/ijap.2021v13i6.42429","article-title":"Development and Characterization of tacrolimus tablet formulations for sublingual administration","volume":"13","author":"Mohanan","year":"2021","journal-title":"Int. J. Appl. Pharm."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.2147\/DDDT.S165693","article-title":"Development of prednisolone-containing eye drop formulations by cyclodextrin complexation and antimicrobial, mucoadhesive biopolymer","volume":"12","author":"Aigner","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1080\/10837450.2016.1180394","article-title":"Evaluation of \u03b3-cyclodextrin effect on permeation of lipophilic drugs: Application of cellophane\/fused octanol membrane","volume":"22","author":"Muankaew","year":"2016","journal-title":"Pharm. Dev. Technol."},{"key":"ref_84","first-page":"718","article-title":"Inclusion complex of hydrochlorothiazide-\u03b3-Cyclodextrin: The effect on aqueous solubility, dissolution rate, bioavailability and the effect on intestinal permeability using Ussing Chamber Technique","volume":"5","author":"Masmoudi","year":"2013","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1002\/jps.22227","article-title":"Comparison of the complexation between methylprednisolone and different cyclodextrins in solution by 1H-NMR and molecular modeling studies","volume":"99","author":"Thi","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12944-016-0284-6","article-title":"Randomized double blind clinical trial on the effect of oral \u03b1-cyclodextrin on serum lipids","volume":"15","author":"Amar","year":"2017","journal-title":"Lipids Health Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.kint.2018.06.031","article-title":"Hydroxypropyl-\u03b2-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis","volume":"94","author":"Mitrofanova","year":"2018","journal-title":"Kidney Int."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.2337\/db13-0399","article-title":"Cyclodextrin protects podocytes in diabetic kidney disease","volume":"62","author":"Guzman","year":"2013","journal-title":"Diabetes"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"M\u00fcller-Deile, J., Sarau, G., Kotb, A.M., Jaremenko, C., Rolle-Kampczyk, U.E., Daniel, C., Kalkhof, S., Christiansen, S.H., and Schiffer, M. (2021). Novel diagnostic and therapeutic techniques reveal changed metabolic profiles in recurrent focal segmental glomerulosclerosis. Sci. Rep., 11, Erratum in Sci. Rep. 2021, 11, 10693.","DOI":"10.1038\/s41598-021-83883-w"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/8760\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:42:24Z","timestamp":1760035344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/8760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,9]]},"references-count":89,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26188760"],"URL":"https:\/\/doi.org\/10.3390\/ijms26188760","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,9]]}}}